NovaBay shareholders clear $10m stock deal

NovaBay Pharmaceuticals (NYSE:NBY) said today that its shareholders have approved a deal to issue 2.4 million shares of common stock as part of a $10.3 million deal with Beijing-based Ch-gemstone Capital.

The private placement is slated to close in January next year, contingent upon approval by regulatory authorities in China.

“We appreciate our stockholders’ support for this financing with an investor that has expressed interest in NovaBay’s long-term success,” president & CEO Mark Sieczkarek said in prepared remarks. “We look forward to completing this financing and plan to use these funds to advance our Avenova growth strategy.”

The biopharmaceutical company is working to develop non-antibiotic products for the topical anti-infective market. NovaBay is developing its Avenova product for the removal of microorganisms and debris on and around the eyelid.

NBY shares closed yesterday at $3.40 apiece, up 6.3%.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Theranos whistleblower Tyler Shultz to participate in keynote interview at DeviceTalks Boston At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos. Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston. REGISTER NOW